Shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $267.43 and traded as low as $264.68. Johnson & Johnson shares last traded at $267.02, with a volume of 9,835,655 shares.
Top Johnson & Johnson Stories
Investors following JNJ have been watching these stories:
- Positive Sentiment: Memorial Hermann-Texas Medical Center will be the first hospital to install the OTTAVA robotic surgical system as part of an early-access commercial launch. This marks a step toward monetizing the platform following its FDA De Novo authorization. Article
- Positive Sentiment: Johnson & Johnson filed for FDA approval to expand CAPLYTA to bipolar I mania or mixed episodes. Two Phase 3 studies showed symptom improvement versus placebo; approval would add a potential fifth adult indication, but remains uncertain. Article
- Negative Sentiment: Healthcare stocks were broadly weaker during Thursday afternoon trading, a sector headwind that may have contributed to pressure on JNJ alongside company-specific news. Sector update
Analysts Set New Price Targets
Several equities research analysts recently issued reports on JNJ shares. Weiss Ratings cut Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research note on Friday, October 23rd. Guggenheim reaffirmed a "buy" rating and issued a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. HSBC upped their target price on Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a report on Thursday, September 10th. TD Cowen reissued a "buy" rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, Leerink Partners lowered their price target on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating for the company in a report on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $275.92.
Get Our Latest Stock Analysis on JNJ
Johnson & Johnson Stock Performance
The stock has a market capitalization of $642.80 billion, a P/E ratio of 40.46, a price-to-earnings-growth ratio of 2.74 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average price of $267.43 and a two-hundred day moving average price of $250.79.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm's revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is presently 81.21%.
Insider Activity at Johnson & Johnson
In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm's stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the transaction, the executive vice president owned 16,994 shares in the company, valued at $4,832,923.66. This represents a 43.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.16% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. PCM Encore LLC increased its stake in Johnson & Johnson by 6.5% in the 3rd quarter. PCM Encore LLC now owns 8,029 shares of the company's stock valued at $2,126,000 after buying an additional 490 shares during the last quarter. Carolina Financial Advisors Inc lifted its position in shares of Johnson & Johnson by 2.1% during the 3rd quarter. Carolina Financial Advisors Inc now owns 2,950 shares of the company's stock worth $781,000 after buying an additional 61 shares in the last quarter. Connors Investor Services Inc. boosted its stake in shares of Johnson & Johnson by 2.9% in the 3rd quarter. Connors Investor Services Inc. now owns 67,636 shares of the company's stock worth $17,906,000 after buying an additional 1,921 shares during the last quarter. Defiance ETFs LLC boosted its stake in shares of Johnson & Johnson by 11.1% in the 3rd quarter. Defiance ETFs LLC now owns 11,322 shares of the company's stock worth $2,997,000 after buying an additional 1,133 shares during the last quarter. Finally, Kestra Advisory Services LLC grew its holdings in shares of Johnson & Johnson by 5.9% in the third quarter. Kestra Advisory Services LLC now owns 483,665 shares of the company's stock valued at $128,045,000 after acquiring an additional 26,805 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.